In two press releases today, Iceland founded Oculis Pharma announces an extension to their Series B round amounting to $15.7m (15.5m CHF), and an expansion to its portfolio through the licensing a novel antibody from Novartis. No financials are disclosed in relation to the licensing. “Oculis is evolving and advancing rapidly,” CEO of Oculis, Dr. … Continue reading Oculis raises $15.7m in extension to B round, licenses new antibody